|
MechanismVEGFR1 modulators |
Active Org.- |
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.KR |
First Approval Date20 Mar 2015 |
|
Mechanism1,3-beta-glucan synthase inhibitors |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 2, Multi-Dose, Double-Blind, Double-Dummy, Active-Control, Randomized Study to Evaluate the Safety, Efficacy and Pharmacokinetic Profile of Two Dosing Regimens of Zabofloxacin for the Treatment of Community-Acquired Pneumonia of Moderate Severity
A double-blind, three-arm study, to evaluate the safety and efficacy of two dosing regimens of zabofloxacin (a fluoroquinolone antibiotic) in community acquired pneumonia.
100 Clinical Results associated with IASO Pharma, Inc.
0 Patents (Medical) associated with IASO Pharma, Inc.
100 Deals associated with IASO Pharma, Inc.
100 Translational Medicine associated with IASO Pharma, Inc.